Table 1 Descriptive statistics of the patient sample at baseline and follow-up.
Baseline | Week 12 follow-up | |
|---|---|---|
N = 36 | N = 24 | |
Age, years | 39.47 (13.82) | 38.83 (13.04) |
Sex, male/female | 27/9 | 18/6 |
Age of onset, years | 26.11 (9.00) | 26.13 (8.68) |
Duration of illness, years | 14.31 (8.77) | 13.92 (8.99) |
Previous clozapine use, Yes/No | 7/29 | 4/20 |
Diagnosis, F20-schizophrenia/F25-schizoaffective | 30/6 | 21/3 |
N = 35 | ||
Previous antipsychotic trials, min; max; median | 2; 10; 3 | 2; 7; 3 |
Number of hospital admissions, min; max; median | 0; 12; 3 | 0; 12; 3 |
Symptoms and Functioning | ||
PANSS-Positive | 18.43 (5.87) | 14.33 (5.10) |
PANSS-Negative | 19.23 (7.51) | 15.29 (5.57) |
PANSS-General | 35.33 (6.94) | 27.04 (5.98) |
PANSS-Total | 72.97 (14.62) | 56.29 (14.11) |
GAF | 45.29 (10.51) | 59.42 (8.66) |
N = 34 | ||
Antipsychotic dose, CPZE/mg per day | 229.21 (187.44) | / |
Clozapine | N = 22 | |
Clozapine dose, daily mg | / | 362.50 (140.31) |
Plasma clozapine, ng/ml | / | 473.18 (30.99) |
Plasma norclozapine, ng/ml | / | 240.00 (123.10) |
